Autoantibodies against nuclear proteins like RNA polymerase I (RNA pol l) are produced in a number of rheumatic autoimmune diseases. Production of antibodies specific for the 190-kD subunit of RNA pol I appears to be characteristic in the patients with systemic sclerosis. Previous investigations have shown that the tight skin (TSK) mouse is an experimental model for systemic sclerosis. In the present study we show that the TSK mice produce high titers of anti-RNA pol I antibodies, both ofIgM and IgG classes. To characterize the immunochemical properties of these antibodies we obtained a large panel of hybridomas from these mice. Analysis of these hybridomas revealed that clonal frequency of autoreactive B cells specific for RNA pol I are higher in the TSK mice than in the controls. mAbs obtained from the TSK mice were specific for the 190-kD subunit and cross-reacted with Esherichia coli and phage T7 RNA polymerases (155-, 150-, and 107-kD polypeptides). We have also demonstrated that these antibodies bind better to the phosphorylated enzymes. The anti-RNA pol I mAbs were divided into three groups in terms of their functional property.
Introduction
Autoimmune diseases are commonly associated with the production of antibodies against nuclear and cytoplasmic en-zymes. Production ofautoantibodies against pyruvate dehydrogenase complex in primary biliary cirrhosis ( 1) , antithyroid peroxidase antibodies in Hashimoto's disease (2) , antiglutamic acid dehydroxylase antibodies in insulin-dependent diabetes (3), anti-transfer RNA synthetase antibodies in polymyositis (4) , and anti-HK ATPase antibodies in pernicious anemia (5) are well known. Autoantibodies against RNA polymerase I (RNA pol I)' have been described in systemic lupus erythematosus (SLE), RA, mixed connective tissue disease (MCTD) (6) , and systemic sclerosis (7) . Similarly these autoantibodies were also found in MRL/lpr mice that develop lupus-and arthritis-like syndromes (8) . Mammalian RNA pol I is a complex enzyme composed of six to eight subunits and has an associated protein kinase NII activity (9) . The subunit specificity of anti-RNA pol I autoantibodies is characteristic for a given systemic autoimmune disease. For example, the antibodies present in RA bind primarily to subunit 1 (S1) whereas SLE sera react with S2 and S5 subunits. Antibodies present in MCTD patients bind only to S4 and, in certain cases, also bind to S3 and S5 (6) . In SLE, it has also been shown that these antibodies react better with phosphorylated enzyme than with the native enzyme (10) .
During the last few years we have studied the production of autoantibodies in tight skin (TSK) mouse, the experimental model for systemic sclerosis, which develops cutaneous hyperplasia accompanied by histopathological alterations and increased transcription of collagen genes (11, 12) . We have shown that TSK mice produce anti-topoisomerase I (topo I) antibodies spontaneously (13) , which are characteristically found only in patients with progressive systemic sclerosis (PSS) but not in patients with CREST syndrome or morphea ( 14) . Interestingly, we have also found that anti-topo I mAbs obtained from the TSK mice and systemic sclerosis patients exhibited the same fine specificities and shared an interspecies crossreactive idiotype ( 15) . The aim of the present study was to determine whether the TSK mice produce anti-RNA pol I antibodies, to study the frequency of autoreactive B cells, and to identify the subunits recognized. The data presented here show that anti-RNA pol I autoantibodies are present in elevated levels in the sera of TSK mice. Frequency of the hybridomas producing anti-RNA pol I antibodies is higher in the TSK mice than in the controls. In addition, we show that these autoantibodies bound to epitopes present on the 1 90-kD subunit of mammalian RNA pol l, on two larger subunits of Escherichia coli RNA polymerase, and on T7 RNA polymerase. These mAbs also exhibit an increased binding to the phosphorylated enzyme and show either inhibitory or enhancing effect on the enzymatic activity of RNA polymerase.
Methods
Mice. TSK and C57BL/6 pa/pa mice were purchased from Jackson Laboratory (Bar Harbor, ME).
Antigens. Rat RNA pol I was purified from Morris hepatoma 3924A cell lysate as described (16) antinucleolar antibodies were used in this study following the methods previously described (7, 20 Filters were washed four times with 5% Na2HPO4, twice with distilled water, and once with ethanol. The incorporation of radioactive label was measured in the liquid-scintillation counter (Pharmacia LKB Biotechnology Inc.). The amount of the enzyme that gives 50% of maximal incorporation was preincubated with various amounts of TSK mAbs ( 15 min at 30°C) and the RNA-synthesizing activity of the enzyme was compared with a similar amount ofthe enzyme that was not preincubated with mAbs.
Extraction ofRNA and Northern analysis. Total cellular RNA was extracted from 3-5 X I07 cells using the guanidium thiocyanate method and Northern analysis was done as previously described (21 ) .
Briefly, 10 Mg of the total RNA was electrophoresed on 1% agaroseformaldehyde gel and blotted onto NCF using 20x SSC (lX SSC = 0.15 M NaCl and 0.015 M sodium citrate) as described (21 ) . The NCFs were baked at 80°C in a vacuum oven for 2 h and prehybridized for 4 h at 42°C with prehybridization solution. The blots were hybridized with the hybridization solution (prehybridization solution containing 10% dextran sulphate and 2 X 106 cpm/ml of random primed VH or VK probe) overnight at 42°C, washed twice with 2x SSC containing 0.1% SDS at room temperature for 15 min, and washed twice with 0.2x SSC containing 0.1% SDS at 65°C for 15 min. NCF blots were dried and autoradiographed on Kodak X-OMAT-AR film, at -70°C for 1-3 d.
V gene probes. The VH gene family probes (VHX24, VH36-O9, VHJ606, VHJS58, VHGAM, VHl 1, VHS107, VHQPC52, and VH7183) and VK gene family probes (VK1, VK2, VK4, VK8, VK9, VKO0, VK19, VK2 1, VK22, VK23, VK24, and VK28) were prepared as described elsewhere ( 18). The lack of crosshybridization of these probes was previously demonstrated (22-24).
Results
Presence ofanti-RNA pol I autoantibodies in TSK mice sera. The presence of autoantibodies to RNA pol I in the sera of 8-and 16-mo-old TSK and C57BL/6 pa/pa mice was determined by RIA. In the preliminary experiments various diluTight-Skin Mouse Anti-RNA Polymerase IAutoantibodies tions of sera were assayed to determine the optimal dilution. IgG and IgM antibodies bound to RNA pol I-coated wells were revealed using '251I-labeled rabbit F(ab') anti-mouse y or ti antibodies. The data depicted in Fig. 1 show that the titers of IgM anti-RNA pol I antibodies were elevated in 31 of 35 TSK mice and the IgG antibodies were elevated in 12 of 35 mice tested. The level ofanti-RNA pol I antibodies in the serum was significantly higher in the TSK mice than in pa/pa mice (P < 0.05 in IgG and P < 0.01 in IgM).
Frequency ofhybridomas producing anti-RNA pol I antibodies. Since the TSK mice have high levels ofanti-RNA pol I antibodies in their sera, we prepared a large panel of hybridomas and selected the clones producing anti-RNA pol I antibodies to study immunochemical and molecular characteristics of anti-RNA pol I autoantibodies. The frequency of B cell clones producing antibodies to RNA pol I was studied using hybridomas obtained from 2-, 8-, and 16-mo-old TSK or 16-mo-old pa/pa mice. Among 350 hybridomas obtained from TSK mice, 6% exhibited binding activity to RNA pol I but none showed binding to centromere protein. On the other hand, from 147 hybridomas derived from pa/pa mice, only 1.4% showed RNA pol I binding activity (Table I) .
From the panel of21 hybridomas producing anti-RNA pol I, 14 hybridomas secreting antibodies showing high binding activity were recloned and further characterized. 11 clones produced IgM antibodies (1 16A7-1 1, L179-7, L272-8, L341-1 1, L342-1 11, L435-4, M25-4, M31-I, M5 1-0, M61-34, and M94-32) and 3 clones produced IgG antibodies (GM3-24, GM5-7, and GM38-26).
Characterization of TSK mice anti-RNA pol I mAbs. The presence of anti-RNA pol I antibodies in the sera of patients with systemic sclerosis (7) or other rheumatic diseases (6) and in MRL mice (8) was studied using rat hepatocyte RNA pol I (25) . In this study, besides the rat enzyme, we have used bacterial (E. coli) and viral (T7 phage) enzymes, since it is well known that self-epitopes on housekeeping enzymes (15) , structural proteins (26) , and cell receptors (27) Fig. 2 A. A majority ofthe TSK antibodies reacted with all three enzymes tested. The rabbit immune serum and PSS sera also recognized all the enzymes. Normal rabbit and human sera did not bind significantly to any of these enzymes (see the legend to Fig. 2 ).
In previous reports it has been shown that the autoantibodies against rat hepatoma RNA pol I were highly specific and did not cross-react with poly(A) polymerase (25) . Therefore, we have examined whether the TSK mAbs also exhibit a similar property by competitive inhibition assays. This was determined by competitive inhibition assays using poly(A) polymerase as an inhibitor. All the mAbs were specific for RNA polymerase. The results obtained with representative mAbs GM5-7 (IgG) and M61-34 (IgM) are shown in Fig. 2 , B and C. E. coli and rat RNA pol I showed higher inhibition than poly(A) polymerase. The control antigen collagen II did not show any inhibitory activity. These data indicate that the TSK mouse autoantibodies do not cross-react with poly(A) polymerase, similar to human autoantibodies. These results also suggest that the rat and E. coli RNA polymerases might share common epitopes.
Binding ofTSK mAbs to phosphorylated and dephosphorylatedRNA polymerases. Previous studies have shown that antibodies present in SLE showed enhanced binding to the phosphorylated enzyme (10) . Conversely, dephosphorylation of the enzyme decreased the binding of lupus anti-RNA pol I as much as 50% (10) . Therefore, we have investigated the effect of phosphorylation and dephosphorylation on the binding of TSK mouse mAbs. Since it has been shown that rat RNA pol I has associated protein kinase activity, we attempted to label the rat enzyme with yATP in an in vitro phosphorylation reaction.
But we could not succeed in phosphorylating the rat enzyme. It is possible that the associated protein kinase activity was lost during the purification procedure since rat RNA pol I also did not show any RNA synthesizing activity (data not shown). Therefore, T7 and E. coli enzymes were used in this experiment. T7 RNA polymerase preparation showed strong phosphorylation (32P radiolabeling) of a 107-kD band (data not shown) and E. coli RNA polymerase exhibited phosphorylation of 150-and 1 55-kD bands (data not shown).
The binding of TSK mouse mAbs to phosphorylated and dephosphorylated enzymes as determined by RIA is shown in Fig. 3 Fig. 4 . TSK mAbs stained the nucleoli of Hep2 cells strongly (Fig. 4 A ) whereas the control BALB/c mAb (specific for IDA10 idiotype) did not exhibit any nucleolar staining (Fig. 4 B) . Colcemid-treated Vero cells incubated with TSK mAbs showed bright fluorescence spots in (Fig. 4 C, Figure 5 . Silver staining of RNA polymerases from various species. Rat and mouse RNA pol I preparations, T7 and E. coli RNA polymerases (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) were gel electrophoresed (see Methods) and silver stained (27) Silver staining. Since the RNA pol I preparations used in our experiments originate from various sources, we confirmed their subunit composition by SDS-gel electrophoresis and silver staining (28) . The results showed that mouse (Fig. 5 A) and rat (Fig. 5 B) RNA pol I were composed of seven subunits ( 190, 120, 65, 42, 25, 21, and 20 kD) as previously described ( 16, 17) . The phage T7 (Fig. 5 C, left lane) and E. coli (Fig. 5 C, right lane) enzymes were composed of a single polypeptide of 107 kD and four subunits of 155, 150, 90, and 37 kD, respectively (29, 30) . It should be noted that the mouse RNA pol I preparation contained several additional bands since the material used is a phosphocellulose chromatographic fraction enriched for enzymatic activity ( 17 ). Western blot analysis. To determine the specificities of TSK mouse mAbs, we studied the binding pattern of these antibodies to the subunits of mammalian, bacterial, and viral enzymes. Western blots of rat RNA pol I (Fig. 6 a) incubated with GM5-7 (IgG) and L 179-7 (IgM) mAbs showed binding to the 190-kD band. The control mAbs 3-9-9 (IgG antiidiotype against antilevan) and LI 85-3 (IgM anti-Fc receptor) did not bind to any of the subunits. Similarly, GM5-7 mAb showed binding to the 1 90-kD polypeptide present in mouse RNA pol I. The isotype-matched control antibodies did not show any binding (Fig. 6 b) .
The binding ofTSK mAbs to T7 and E. coli RNA polymerase was also confirmed by Western blot analysis. The results clearly showed that TSK mAbs bound to T7 RNA polymerase ( 107 kD) and two larger subunits ( 155 and 150 kD) of E. coli enzyme. Further, these mAbs also showed higher reactivity (higher intensity) to phosphorylated enzymes compared with native enzymes. Representative results are shown in Fig. 6 , c and d. The binding of TSK mAbs GM5-7 and L179-7 is stronger to phosphorylated T7 RNA polymerase (Fig. 6 c, lanes 2 and 4) and to phosphorylated E. coli RNA polymerase (Fig. 6 d, lanes 2 and 4) than to native T7 and E. coli enzymes (Fig. 6 c, lanes 1 and 3, and d, lanes 1 and 3) . Isotype-matched control mAbs 3-9-9 and L185-3 did not show any binding to these enzymes (Fig. 6 c, lanes 5-8, and d, lanes 5-8) .
Effect ofTSK mouse mAbs on RNA polymerase enzymatic activity. Since it has been shown previously that human anti-RNA pol I antibodies obtained from SLE, MCTD, and RA inhibited the RNA synthesizing activity of the rat enzyme (6) and that PSS IgG autoantibodies suppressed the ribosomal RNA synthesis after microinjection into X-laevis oocytes (7), we studied the effect of TSK anti-RNA pol I antibodies on the enzymatic activity of RNA polymerase. As only small amounts of purified rat and mouse RNA pol I were available and because all of our mAbs bound to both mammalian and bacterial enzymes, we used E. coli RNA polymerase to study the effect of antibodies on enzymatic activity. On the basis of their effects on RNA synthesis, we grouped these antibodies into three categories: mAbs exhibiting an inhibitory effect (M31-1, M61-34, and L1 79-7; Fig. 7 A) ; mAbs that enhance the enzymatic activity (GM38-26 or GM5-7; Fig. 7 B) ; and mAbs that did not have any effect on the enzymatic activity (M94-32; Fig. 7 A) . The results obtained suggested that the TSK mouse mAbs exhibiting inhibitory activity and enhancing activity should bind to different epitopes. To verify this hypothesis, we studied the binding activity ofthese antibodies to E. coli RNA polymerase by competitive inhibition assays. This was done by incubating the radiolabeled inhibitory antibody (L 179-7) with a cold enhancing antibody (GM5-7) on antigen (E. coli RNA polymerase)-coated plates. Similarly, the radiolabeled enhancing antibody was competed with the cold inhibitory antibody. The bound radioactivity was measured and the percentage inhibition was calculated. The results revealed that only homologous cold antibodies inhibited the binding of radiolabeled mAbs to the enzyme (Fig. 8 ). These data demonstrate that the inhibitory and enhancing antibodies recognized distinct epitopes.
VH and VK gene usage in TSK mice anti-RNA pol I mAbs. We have investigated the usage of V gene family in the TSK mice anti-RNA pol I antibodies to understand the molecular basis of the autoantibody specificity and to determine whether there is a bias toward using certain V gene families. The results are summarized in Table II . Autoradiographs VHJ558 gene family, 5 of 13 (38%) hybridomas use VKl, and 4 of 13 (31%) use VK8 (Table II) . The comparison between the expected and observed frequencies is shown in Table III . Although only a small panel of hybridomas were analyzed, our data suggest that there is a bias in the usage of both VHJ558, VK8, and VKl gene families among the TSK anti-RNA pol I
antibodies.
Discussion
In the present communication we demonstrate that TSK mice spontaneously produce high titers of anti-RNA pol I autoanti- bodies (Fig. 1) . The high frequency of hybridomas producing anti-RNA pol I antibodies observed in TSK mice (Table I ) is in agreement with the above results. The presence of anti-RNA pol I antibodies has been described in a number of autoimmune diseases, including scleroderma (6, 7). Human anti-RNA pol I autoantibodies are characterized by their ability to bind to native enzyme located in nucleoli and particularly in the fibrillar regions of nucleoli after drug-induced nucleolar segregation (7) ; to bind to several subunits of the enzyme (6, 7) ; to inhibit the enzymatic activity as assessed by in vitro inhibition ofRNA synthesis (6) or by in vivo inhibition of ribosomal RNA synthesis after microinjection of the antibodies into the nucleus of X-laevis oocytes (7); and to show increased binding to phosphorylated enzyme ( 10) . To determine whether these characteristics are also shared by TSK anti-RNA pol I antibodies, we prepared a large panel ofmAbs and studied their properties. The results ofRIA, using purified RNA pol I enzyme preparations, show that TSK mAbs bind not only to mammalian (rat) enzyme but also to bacterial and viral enzymes (Fig. 2 A) . Here we have demonstrated that rabbit and human anti-RNA pol I antibodies also bound to prokaryotic enzymes similar to TSK mouse autoantibodies.
Previous studies showed that rabbit and scleroderma anti-RNA pol I antibodies gave speckled-type nucleolar staining and the staining of fibrillar regions of drug-induced segregated nucleoli (7, 31, 32) . Our immunofluorescence studies demonstrated that TSK mAbs gave a similar speckled nucleolar staining pattern with Hep2 cells (Fig. 4 A) , bright fluorescent dots on colcemid-treated Vero cells (Fig. 4 C) , and the staining of fibrillar regions of actinomycin D-treated Vero cells (Fig. 4   D) . However, they did not show the necklace-type nucleolar staining of actinomycin D-treated Vero cells, which was observed with scleroderma autoantibodies (7).
Reimer et al. (7) showed, by immunoprecipitation of[35S- (Fig. 6 ). This distinct reactivity pattern could be attributed to the differences in the epitopes recognized by monoclonal and polyclonal autoantibodies. It is important to point out that the majority of TSK mAbs bound to the murine enzyme, which represents the putative autoantigen that was able to activate the autoreactive clones. Our studies further showed that the TSK autoantibodies bound to T7 RNA polymerase and to the two large subunits (155 and 150 kD) of E. coli RNA polymerase (Fig. 6 ). Another important property ofhuman anti-RNA pol I autoantibodies is their ability to inhibit the enzymatic activity. In contrast to the polyclonal human anti-RNA pol Iautoantibodies, which showed only inhibitory effect on the enzymatic activity (6, 7) , TSK mouse mAbs showed three different patterns of reactivity (Fig. 7) . It is likely that the clonality of mAbs enabled us to distinguish these three categories, which have not been observed in the experiments with polyclonal antibodies. The first group, represented by IgM mAbs, inhibits the enzymatic activity, indicating that these antibodies bind to an epitope associated with the catalytic site. Previous observations suggest that the larger subunits play an important role in the enzymatic activity (35) . In fact, mAbs belonging to this group ( L179-7) show binding to the 155-and 150-kD subunits of E. coli RNA polymerase and the 190-kD protein of mammalian enzymes (Fig. 6) . The second group exhibits enhancement of the enzymatic activity, which is possibly related to an allosteric effect described by Monod et al. (36) . Because mAbs of this group also bind to the larger subunits of the enzymes (Fig. 6) , we did competitive inhibition RIA to determine whether the mAbs of the first and second groups bind to different epitopes.
The results clearly show that the inhibiting and enhancing mAbs recognized distinct epitopes, since the antibodies of the first group did not compete with the antibodies of the second group (Fig. 8) . The third group is represented by "neutral"
antibodies. These mAbs may bind to an epitope that does not affect the three-dimensional conformation of the enzyme. We have not determined the subunit specificity ofthese antibodies. (37) . In contrast, our data from V gene expression analysis suggest that the genes encoding the TSK mouse anti-RNA pol I antibodies are primarily derived from J558 VH gene family (79%) and a few VK families (i.e., VKl and VK8) (Tables II and  III) bodies also encode an idiotype that is involved in the induction of the autoreactive clones. In fact, we have shown the presence ofantiidiotypic antibodies against anti-topo I antibodies in the TSK mice ( 13) .
In conclusion, our data demonstrate that TSK mice spontaneously produce anti-RNA pol I autoantibodies similar to those present in several autoimmune diseases (6) (7) (8) 10 ). Therefore, this mutant strain can be a valuable model for studying not only the alterations in collagen metabolism but also autoimmunity associated with connective tissue diseases. The TSK mouse anti-RNA pol I autoantibodies analyzed in the current study exhibit similar binding activity in RIA to those described by Stetler et al. (6) in SLE, RA, and MCTD. Our studies demonstrated that TSK antibodies resemble human autoantibodies in binding to the large subunit ofthe enzyme (7), in exhibiting increased reactivity to phosphorylated enzyme ( 10), in inhibiting the enzymatic activity (6, 7) , and in staining nucleoli with speckled pattern in immunofluorescence (7) . The TSK mAbs differ from scleroderma polyclonal antibodies by the lack of reactivity to smaller subunits, by exhibiting enhancing effect on the enzymatic activity in some cases, and by the lack of necklace staining pattern in immunofluorescence ofactinomycin D-treated Vero cells. Proofthat TSK anti-RNA pol I antibodies are identical to those that distinguish scleroderma remains to be determined. Studies in progress are aimed to determine the epitope specificity of TSK mAbs and human scleroderma mAbs, using fusion peptides obtained from cDNAs that encode for RNA pol I 190-kD subunit.
